Glaxosmithkline plc
Glaxosmithkline: Q1 2006 results
Although Glaxosmithkline’s growth is slightly lower than Astrazeneca’s it has the advantage of being far more diversified and less dependent on a small number of block-buster products: no single drug added more than £112 of Glaxosmithkline’s £459m (10% at CER) increase in sales, almost all major drugs produced significant growth and there were no major […]
Glaxosmithkline Q3 results
Glaxosmithkline continued the reasonable level of underlying growth which we saw earlier in the year with sales up 9% and EPS up 16% (both at CER). Glaxosmithkline has raised its official earnings guidance for the year to “mid-teens” EPS growth. The company also accidentally disclosed an internal estimate of 79.9p (17%). This close to most […]
Paxil CR supply resumed
Glaxosmithkline has solved its manufacturing problems and resumed the supply of Paxil CR to the US. Supplies of the other drug affected, Avandamet, are expected to resume in two weeks.
Glaxo has been able to deliver within the timetable it promised and the news removes once uncertainty, although the short term nature of the problem and […]
Glaxosmithkline Q1 results
Glaxosmithkline’s Sales growth in the US was almost wiped out by the interruptions to the supply of Paxil CR, but this is a short term problem and underlying growth was strong with sales (excluding the impact of Paxil CR problems) up 13% in the US and 10% in Europe.
Glaxosmithkline
Competition from generics was clearly Glaxosmithkline’s biggest problem in 2004 with big falls in the sales of a number of major drugs - the biggest declines (in absolute terms) were sales of the old formulations of anti-depressants Paxil (sales fell £752m at CER) and Wellbutrin (sales down £505m at CER). There were a number of […]
Random picks: Berkeley | Burberry | Collins Stewart | Easyjet | Greggs | Johnson Matthey | Smiths | Tullow Oil | Wolseley | Johnston Press